home All News open_in_new Full Article

New breast cancer drug wins FDA approval after slashing progression risk by nearly 40%

The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement in progression-free survival for breast cancer.


today 43 h. ago attach_file Politics

attach_file Science
attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Science
attach_file Politics
attach_file Politics


ID: 2786359758
Add Watch Country

arrow_drop_down